NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03758716,An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT03758716,,COMPLETED,The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis,YES,Atopic Dermatitis,"DRUG: FB825, FB825-15D11, Anti-CemX","% Change From Baseline in Total IgE, Detect total IgE in serum by ImmunoCAP., Day 169|% Change From Baseline in Allergen-specific IgE, Detect specific IgE in serum by ImmunoCAP. (ex. Ragweed), Day 169","Change From Baseline in Total IgE, Detect total IgE in serum by ImmunoCAP., Day 8, 15, 29, 57, and day 85 (And Day 92, 99, 113, 141 and 169 if received the second dose of FB825)|% Change From Baseline in Allergen-specific IgE, Detect specific IgE in serum by ImmunoCAP. (Dog dander), Day 8, 15, 29, 57, and day 85 (And Day 92, 99, 113, 141 and 169 if received the second dose of FB825)|% Changes From Baseline in Irritability Visual Analogue Scale (VAS), VAS measurement follow the normal by Principal Investigator, range from 0-20. The lower the scores the better situation of the patient., Days 85|% Changes From Baseline in Eczema Area and Severity Index (EASI), EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient., Day 85|% Changes From Baseline in Severity Scoring of Atopic Dermatitis Index (SCORAD), SCORAD measurement follow the normal by Principal Investigator, range from 0-103. The lower the scores the better situation of the patient., Days 169|% Changes From Baseline in Investigator Global Assessment (IGA) for Atopic Dermatitis, IGA measurement follow the normal by Principal Investigator, range from 0-4. The lower the scores the better situation of the patient., Days 169|% Changes From Baseline in Body Surface Area (BSA) Involved in Atopic Dermatitis, BSA measurement follow the normal by Principal Investigator, range from 0-100. The lower the scores the better situation of the patient., Days 169|Safety Will be Assessed by Monitoring and Recording of Adverse Events (AEs) and Serious Adverse Event (SAEs), Safety will be assessed by monitoring and recording of adverse events (AEs) and serious adverse event (SAEs); physical examination findings and vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature), clinical laboratory test results (hematology, coagulation, serum chemistry \[including liver function tests, blood glucose level\], and urinalysis); 12-lead ECG results., through study completion, an average of 1 year.|% Changes From Baseline in Eczema Area and Severity Index (EASI), EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient., Day 57|% Changes From Baseline in Eczema Area and Severity Index (EASI), EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient., Day 113|% Changes From Baseline in Eczema Area and Severity Index (EASI), EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient., Day 141|% Changes From Baseline in Eczema Area and Severity Index (EASI), EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient., Day 169",,Fountain Biopharma Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,FB825CLIIS-01-AD,2017-07-03,2019-01-28,2019-09-19,2018-11-29,2021-01-08,2021-04-22,"National Taiwan University Hospital, Taipei, Taiwan","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/16/NCT03758716/Prot_SAP_000.pdf"
